A detailed history of Lsv Asset Management transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 30,400 shares of PBYI stock, worth $90,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,400
Previous 30,400 -0.0%
Holding current value
$90,896
Previous $99,000 21.21%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$4.29 - $7.4 $241,316 - $416,257
-56,251 Reduced 64.92%
30,400 $161,000
Q3 2023

Nov 03, 2023

SELL
$2.63 - $4.09 $283,777 - $441,311
-107,900 Reduced 55.46%
86,651 $228,000
Q1 2023

May 02, 2023

SELL
$2.21 - $4.82 $14,586 - $31,812
-6,600 Reduced 3.28%
194,551 $601,000
Q4 2022

Feb 08, 2023

BUY
$2.12 - $5.08 $40,390 - $96,784
19,052 Added 10.46%
201,151 $851,000
Q3 2022

Nov 07, 2022

BUY
$2.27 - $3.84 $413,364 - $699,260
182,099 New
182,099 $432,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $136M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.